Transport, enzymatic activity, and stability of mutant sulfamidase (SGSH) identified in patients with mucopolysaccharidosis type III A
- PMID: 15146460
- DOI: 10.1002/humu.20037
Transport, enzymatic activity, and stability of mutant sulfamidase (SGSH) identified in patients with mucopolysaccharidosis type III A
Abstract
Mucopolysaccharidosis type IIIA (MPSIIIA) is an autosomal recessive lysosomal storage disease caused by mutations in the N-sulfoglucosamine sulfohydrolase gene (SGSH; encoding sulfamidase, also sulphamidase) leading to the lysosomal accumulation and urinary excretion of heparan sulfate. Considerable variation in the onset and severity of the clinical phenotype is observed. We report here on expression studies of four novel mutations: c.318C>A (p.Ser106Arg), c.488T>C (p.Leu163Pro), c.571G>A (p.Gly191Arg), and c.1207_1209delTAC (p.Tyr403del), and five previously known mutations: c.220C>T (p.Arg74Cys), c.697C>T (p.Arg233X), c.1297C>T (p.Arg433Trp), c.1026dupC (p.Leu343fsX158), and c.1135delG (p.Val379fsX33) identified in MPSIIIA patients. Transient expression of mutant sulfamidases in BHK or CHO cells revealed that all the mutants were enzymatically inactive with the exception of c.318C>A (p.Ser106Arg), which showed 3.3% activity of the expressed wild-type enzyme. Western blot analysis demonstrated that the amounts of expressed mutant sulfamidases were significantly reduced compared with cells expressing wild type. No polypeptides were immunodetectable in extracts of cells transfected with the cDNA carrying the c.697C>T (p.Arg233X) nonsense mutation. In vitro translation and pulse-chase experiments showed that rapid degradation rather than a decrease in synthesis is responsible for the low, steady-state level of the mutant proteins in cells. The amounts of secreted mutant precursor forms, the cellular stability, the proteolytic processing, and data from double-label immunofluorescence microscopy suggest that the degradation of the majority of newly synthesized c.220C>T (p.Arg74Cys), c.571G>A (p.Gly191Arg), c.1297C>T (p.Arg433Trp), c.1026dupC (p.Leu343fsX158), and c.1135delG (p.Val379fsX33) mutant proteins probably occurs in the ER, whereas c.488T>C (p.Leu163Pro) mutant protein showed instability in the lysosomes.
Copyright 2004 Wiley-Liss, Inc.
Similar articles
-
Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.Hum Mutat. 2001 Oct;18(4):264-81. doi: 10.1002/humu.1189. Hum Mutat. 2001. PMID: 11668611 Review.
-
Residual activity and proteasomal degradation of p.Ser298Pro sulfamidase identified in patients with a mild clinical phenotype of Sanfilippo A syndrome.Am J Med Genet A. 2011 Jul;155A(7):1634-9. doi: 10.1002/ajmg.a.34053. Epub 2011 Jun 10. Am J Med Genet A. 2011. PMID: 21671382
-
The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome).Hum Mutat. 2008 May;29(5):770. doi: 10.1002/humu.20738. Hum Mutat. 2008. PMID: 18407553
-
Purification and characterization of recombinant murine sulfamidase.Mol Genet Metab. 2004 Nov;83(3):239-45. doi: 10.1016/j.ymgme.2004.07.016. Mol Genet Metab. 2004. PMID: 15542395
-
Sanfilippo syndrome type C: mutation spectrum in the heparan sulfate acetyl-CoA: alpha-glucosaminide N-acetyltransferase (HGSNAT) gene.Hum Mutat. 2009 Jun;30(6):918-25. doi: 10.1002/humu.20986. Hum Mutat. 2009. PMID: 19479962 Review.
Cited by
-
Bioinformatics classification of mutations in patients with Mucopolysaccharidosis IIIA.Metab Brain Dis. 2019 Dec;34(6):1577-1594. doi: 10.1007/s11011-019-00465-6. Epub 2019 Aug 5. Metab Brain Dis. 2019. PMID: 31385193 Free PMC article.
-
Growth charts for patients with Sanfilippo syndrome (Mucopolysaccharidosis type III).Orphanet J Rare Dis. 2019 May 2;14(1):93. doi: 10.1186/s13023-019-1065-x. Orphanet J Rare Dis. 2019. PMID: 31046785 Free PMC article.
-
Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study.Eur J Pediatr. 2019 May;178(5):739-753. doi: 10.1007/s00431-019-03341-8. Epub 2019 Feb 26. Eur J Pediatr. 2019. PMID: 30809705 Free PMC article. Clinical Trial.
-
Prediction of phenotypic severity in mucopolysaccharidosis type IIIA.Ann Neurol. 2017 Nov;82(5):686-696. doi: 10.1002/ana.25069. Epub 2017 Oct 26. Ann Neurol. 2017. PMID: 29023963 Free PMC article.
-
Structure of sulfamidase provides insight into the molecular pathology of mucopolysaccharidosis IIIA.Acta Crystallogr D Biol Crystallogr. 2014 May;70(Pt 5):1321-35. doi: 10.1107/S1399004714002739. Epub 2014 Apr 30. Acta Crystallogr D Biol Crystallogr. 2014. PMID: 24816101 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
